MeSH D054179 - hereditary angioedemas
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000081208:Hereditary complement deficiency diseases
0 Companies
0 Drugs
Success rate
D000799:Angioedema
D054179:
Hereditary angioedemas
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Icatibant | Icatibant Accord | 2021-07-16 | |||
| Alembic Pharmaceuticals | Icatibant | Icatibant | 2024-06-14 | |||
| BioCryst Pharmaceuticals | Berotralstat | Orladeyo | 2021-04-30 | $404.357 M | Q4/23-Q3/24 | |
| Cipla | Icatibant | Icatibant | 2020-07-13 | |||
| Dr Reddys Laboratories | Icatibant | Icatibant | 2020-10-05 | |||
| Eugia Pharma Specialties | Icatibant | Icatibant | 2023-08-14 | |||
| Fresenius Kabi | Icatibant | Icatibant | 2020-06-18 | |||
| Glenmark Pharmaceuticals | Icatibant | Icatibant | 2021-05-21 | |||
| Jiangsu Hansoh Pharmaceutical Group | Icatibant | Icatibant | 2020-03-09 | |||
| Nang Kuang Pharmaceutical | Icatibant | Icatibant | 2020-12-16 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
56%5/9
Phase 2
83%5/6
Phase 3
58%11/19
Approved: 6Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use